Seno-suppressive molecules as new therapeutic perspectives in rheumatic diseases

Biochem Pharmacol. 2019 Jul:165:126-133. doi: 10.1016/j.bcp.2019.03.017. Epub 2019 Mar 13.

Abstract

Over the past years, through in vitro studies and unique animal models, biologists and clinicians have demonstrated that cellular senescence is at the root of numerous age-related chronic diseases including osteoarthritis and osteoporosis. This non-proliferative cellular syndrome can modify other surrounding tissue-resident cells through the establishment of a deleterious catabolic and inflammatory microenvironment. Targeting these deleterious cells through local or systemic seno-therapeutic agent delivery in pre-clinical models improves dramatically clinical signs and extends health span. In this review, we will summarize the current knowledge on cellular senescence, list the different strategies for identifying seno-suppressive therapeutic agents and their translations to rheumatic diseases.

Keywords: Osteoarthritis; Osteoporosis; Rheumatology; Senescence; Therapies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autophagy
  • Cellular Senescence / drug effects*
  • Humans
  • Longevity / drug effects
  • Nucleotidyltransferases / physiology
  • Osteoarthritis / drug therapy
  • Osteoporosis / drug therapy
  • Osteoporosis / etiology
  • Rheumatic Diseases / drug therapy*

Substances

  • Nucleotidyltransferases
  • cGAS protein, human